Research

Researchers have identified two FDA-approved drugs that may be effective against the Ebola virus. This could shorten the time for developing new treatments.

HEALTHLINE NEWS  by  Shawn Radcliffe                                                         June 3, 2015

With a fast-moving epidemic like Ebola, doctors need to make use of every tool at their disposal. This includes giving a second life to already-approved drugs....

One research team is hoping to ease the epidemic by shortening the lengthy drug development process.

Their approach? Sifting through hundreds of existing drugs and other compounds for ones that might work against the Ebola virus....

Additional screening narrowed the list down to two potential drug candidates: Bepridil, a calcium channel blocker used to treat heart disease, and sertraline, an antidepressant more commonly known as Zoloft.

Both drugs are already approved by the FDA, although not for use against the Ebola virus.

Read complete story.

http://www.healthline.com/health-news/zoloft-could-be-a-treatment-for-ebola-virus-060315#1

MEDICAL NEWS TODAY                                                    June 2, 2015
(Scroll down for study.)
Last year, in the 3 days before the outbreak was officially announced, over 60 million people received tweets about the Ebola outbreak in West Africa, say the authors of a new study published in the American Journal of Infection Control that investigates the useful role that Twitter can play in outbreak monitoring and control.

In the 3 days prior to Nigeria's official announcement about Ebola, Twitter users had already shared around 1,500 tweets about the outbreak....

Social media allow users to play active roles in spreading news. Users can share insights, opinions, fears and ideas, outside the contexts of conventional public health channels.

For their study, two researchers from Columbia University School of Nursing in New York, analyzed Ebola-related tweets posted over a week in the early stages of the West African outbreak - from July 24th to August 1st 2014....

From crisis to sustainable development: lessons from the Ebola outbreak

who.int - May 10, 2015

. . . three changes will do the most to improve the world’s collective defence against the infectious disease threat.

First, invest in building resilient communities and well-performing health systems that integrate public health and primary health care. Ideally, health systems should aim for universal health coverage, so the poor are not left behind. This requires new thinking and a new approach to health development.

Second, develop the systems, capacities, and financing mechanisms needed to build surge capacity for responding to outbreaks and humanitarian emergencies.

Third, create incentives for R&D for new medical products for diseases that primarily affect the poor. A fair and just world should not let people die for what boils down to market failure and poverty.

These three things also fit well with the coming agenda for sustainable development that seeks to distribute the benefits of economic growth more evenly and respects our planet’s fragile resources.

BUSINESS STANDARD                                                                        April 27, 2015

HYDERABAD, India --Ella Foundation, which has taken up research for finding a potential vaccine for the deadly Ebola virus, today said it had successfully completed preliminary studies on the virus, which was responsible for high fatalities among humans in central Africa.

The Hyderabad-based foundation said it had completed the preliminary animal (with mice) experiments of the virus' glycoprotein with the targeted adenovirus, and the "immune response results have been good", which would be followed by toxicology tests and the subsequent clinical trials involving human beings.

Adenoviruses are responsible for respiratory infections, gastroenteritis, cystitis, and primary pneumonia in humans, and are therefore used as a clear target to understand the human immunity characteristics in laboratory. However, the efficacy of the vaccine is judged by the outcomes seen in human trials.

Read complete story.

http://www.business-standard.com/article/current-affairs/ella-foundation-announces-key-outcomes-in-ebola-vaccine-research-115042700631_1.html